vs
宜瑞安（INGR）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
宜瑞安的季度营收约是通用电气医疗的1.2倍（$1.8B vs $1.4B），宜瑞安净利率更高（9.5% vs 3.6%，领先5.9%），通用电气医疗同比增速更快（12.2% vs -2.4%），宜瑞安自由现金流更多（$270.0M vs $130.2M），过去两年通用电气医疗的营收复合增速更高（13.0% vs -3.4%）
宜瑞安（Ingredion Inc.）是总部位于美国伊利诺伊州的食品饮料配料供应商，主打产品包括淀粉、非转基因甜味剂、甜菊糖、豌豆蛋白等，以玉米、木薯、马铃薯、谷物、果蔬等为原料，产品供应食品、饮料、酿造、制药等多个行业，在全球44个站点拥有约1.2万名员工，客户覆盖超120个国家。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
INGR vs OPCH — 直观对比
营收规模更大
INGR
是对方的1.2倍
$1.4B
营收增速更快
OPCH
高出14.6%
-2.4%
净利率更高
INGR
高出5.9%
3.6%
自由现金流更多
INGR
多$139.8M
$130.2M
两年增速更快
OPCH
近两年复合增速
-3.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.4B |
| 净利润 | $167.0M | $51.8M |
| 毛利率 | 24.5% | 19.0% |
| 营业利润率 | 12.5% | 5.9% |
| 净利率 | 9.5% | 3.6% |
| 营收同比 | -2.4% | 12.2% |
| 净利润同比 | 72.2% | -3.8% |
| 每股收益（稀释后） | $2.58 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INGROPCH
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.8B | $1.4B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.9B | $1.3B | ||
| Q2 24 | $1.9B | $1.2B | ||
| Q1 24 | $1.9B | $1.1B |
净利润INGROPCH
| Q4 25 | $167.0M | — | ||
| Q3 25 | $171.0M | $51.8M | ||
| Q2 25 | $196.0M | $50.5M | ||
| Q1 25 | $197.0M | $46.7M | ||
| Q4 24 | $97.0M | $60.1M | ||
| Q3 24 | $188.0M | $53.9M | ||
| Q2 24 | $148.0M | $53.0M | ||
| Q1 24 | $216.0M | $44.8M |
毛利率INGROPCH
| Q4 25 | 24.5% | — | ||
| Q3 25 | 25.1% | 19.0% | ||
| Q2 25 | 26.0% | 19.0% | ||
| Q1 25 | 25.7% | 19.7% | ||
| Q4 24 | 24.9% | 21.3% | ||
| Q3 24 | 25.6% | 20.1% | ||
| Q2 24 | 23.7% | 20.3% | ||
| Q1 24 | 22.2% | 20.8% |
营业利润率INGROPCH
| Q4 25 | 12.5% | — | ||
| Q3 25 | 13.7% | 5.9% | ||
| Q2 25 | 14.8% | 5.8% | ||
| Q1 25 | 15.2% | 5.9% | ||
| Q4 24 | 9.0% | 6.9% | ||
| Q3 24 | 14.3% | 6.7% | ||
| Q2 24 | 12.8% | 6.6% | ||
| Q1 24 | 11.3% | 6.0% |
净利率INGROPCH
| Q4 25 | 9.5% | — | ||
| Q3 25 | 9.4% | 3.6% | ||
| Q2 25 | 10.7% | 3.6% | ||
| Q1 25 | 10.9% | 3.5% | ||
| Q4 24 | 5.4% | 4.8% | ||
| Q3 24 | 10.1% | 4.2% | ||
| Q2 24 | 7.9% | 4.3% | ||
| Q1 24 | 11.5% | 3.9% |
每股收益（稀释后）INGROPCH
| Q4 25 | $2.58 | — | ||
| Q3 25 | $2.61 | $0.32 | ||
| Q2 25 | $2.99 | $0.31 | ||
| Q1 25 | $3.00 | $0.28 | ||
| Q4 24 | $1.43 | $0.36 | ||
| Q3 24 | $2.83 | $0.31 | ||
| Q2 24 | $2.22 | $0.30 | ||
| Q1 24 | $3.23 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $309.8M |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $4.3B | $1.4B |
| 总资产 | $7.9B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资INGROPCH
| Q4 25 | $1.0B | — | ||
| Q3 25 | $915.0M | $309.8M | ||
| Q2 25 | $861.0M | $198.8M | ||
| Q1 25 | $837.0M | $171.4M | ||
| Q4 24 | $997.0M | $412.6M | ||
| Q3 24 | $877.0M | $483.0M | ||
| Q2 24 | $505.0M | $376.9M | ||
| Q1 24 | $438.0M | $219.5M |
总债务INGROPCH
| Q4 25 | — | — | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
股东权益INGROPCH
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.2B | $1.4B | ||
| Q2 25 | $4.2B | $1.4B | ||
| Q1 25 | $4.0B | $1.4B | ||
| Q4 24 | $3.8B | $1.4B | ||
| Q3 24 | $4.0B | $1.4B | ||
| Q2 24 | $3.7B | $1.4B | ||
| Q1 24 | $3.7B | $1.4B |
总资产INGROPCH
| Q4 25 | $7.9B | — | ||
| Q3 25 | $7.8B | $3.5B | ||
| Q2 25 | $7.8B | $3.4B | ||
| Q1 25 | $7.5B | $3.3B | ||
| Q4 24 | $7.4B | $3.4B | ||
| Q3 24 | $7.5B | $3.4B | ||
| Q2 24 | $7.2B | $3.3B | ||
| Q1 24 | $7.3B | $3.2B |
负债/权益比INGROPCH
| Q4 25 | — | — | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.82× | ||
| Q4 24 | — | 0.79× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.79× | ||
| Q1 24 | — | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $405.0M | $139.4M |
| 自由现金流经营现金流 - 资本支出 | $270.0M | $130.2M |
| 自由现金流率自由现金流/营收 | 15.4% | 9.1% |
| 资本支出强度资本支出/营收 | 7.7% | 0.6% |
| 现金转化率经营现金流/净利润 | 2.43× | 2.69× |
| 过去12个月自由现金流最近4个季度 | $511.0M | $220.7M |
8季度趋势，按日历期对齐
经营现金流INGROPCH
| Q4 25 | $405.0M | — | ||
| Q3 25 | $277.0M | $139.4M | ||
| Q2 25 | $185.0M | $90.3M | ||
| Q1 25 | $77.0M | $-7.2M | ||
| Q4 24 | $436.0M | $36.1M | ||
| Q3 24 | $479.0M | $160.4M | ||
| Q2 24 | $312.0M | $195.7M | ||
| Q1 24 | $209.0M | $-68.8M |
自由现金流INGROPCH
| Q4 25 | $270.0M | — | ||
| Q3 25 | $172.0M | $130.2M | ||
| Q2 25 | $84.0M | $81.2M | ||
| Q1 25 | $-15.0M | $-16.6M | ||
| Q4 24 | $311.0M | $25.8M | ||
| Q3 24 | $429.0M | $150.7M | ||
| Q2 24 | $257.0M | $185.9M | ||
| Q1 24 | $144.0M | $-74.6M |
自由现金流率INGROPCH
| Q4 25 | 15.4% | — | ||
| Q3 25 | 9.5% | 9.1% | ||
| Q2 25 | 4.6% | 5.7% | ||
| Q1 25 | -0.8% | -1.2% | ||
| Q4 24 | 17.3% | 2.0% | ||
| Q3 24 | 22.9% | 11.8% | ||
| Q2 24 | 13.7% | 15.1% | ||
| Q1 24 | 7.7% | -6.5% |
资本支出强度INGROPCH
| Q4 25 | 7.7% | — | ||
| Q3 25 | 5.8% | 0.6% | ||
| Q2 25 | 5.5% | 0.6% | ||
| Q1 25 | 5.1% | 0.7% | ||
| Q4 24 | 6.9% | 0.8% | ||
| Q3 24 | 2.7% | 0.8% | ||
| Q2 24 | 2.9% | 0.8% | ||
| Q1 24 | 3.5% | 0.5% |
现金转化率INGROPCH
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.62× | 2.69× | ||
| Q2 25 | 0.94× | 1.79× | ||
| Q1 25 | 0.39× | -0.15× | ||
| Q4 24 | 4.49× | 0.60× | ||
| Q3 24 | 2.55× | 2.98× | ||
| Q2 24 | 2.11× | 3.69× | ||
| Q1 24 | 0.97× | -1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INGR
| Food And Industrial Ingredients LATAM Segment | $599.0M | 34% |
| Texture And Healthful Solutions Segment | $598.0M | 34% |
| Food And Industrial Ingredients U.S.Canada Segment | $486.0M | 28% |
| Other | $74.0M | 4% |
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
